Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Autolus Therapeutics plcNASDAQ: AUTL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$56.94M, compared with -$55.52M a year earlier. Trailing-twelve-month EBITDA was -$230.8M.

Context

  • EBITDA amounted to 331.2% of revenue in FY2025, down 1971.9 pp from a year earlier.
  • EBITDA grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 6 analysts of -$147.19M (+41.2%) for the fiscal year ending Dec 2026, a step up from the -7.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$56.94M+13.7% QoQ
Last fiscal yearDec 2025
-$250.26M-7.4% YoY
LTMMar 2026
-$230.8M+3.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.6%-7.4%-4.8 pp
1 year-7.4%+41.2%+48.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(250.26M) USD
Year-over-year change
-7.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 EBITDA of -$230.8M is the 9th highest of the 10 companies compared; the peer median is -$89.9M.
  • Its year-over-year change of +3.4% is the 6th highest of 10, against a peer median of +4.6%.
  • EBITDA amounts to 249.3% of revenue for AUTL, versus a peer median of 89.7%.
AUTL Competitors Peer median
EBITDA for AUTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M +154.3%—7.3%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$5.48M +4.6%—23.7%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M -143.9%—89.7%
CLLSCellectis S.A.LTM Mar 2026-$51.11M -57.3%—75.1%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$89.9M -1211.1%——
CRBUCaribou Biosciences, Inc.LTM Mar 2026-$111.97M +23.4%—999.5%
FATEFate Therapeutics, Inc.LTM Mar 2026-$117.42M +23.4%—1859.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M +32.7%——
AUTLAutolus Therapeutics plcLTM Mar 2026-$230.8M +3.4%—249.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$238.99M -27.7%—770932.3%
Peer median (excluding AUTL) -$89.9M+4.6%—89.7%

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.